Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-10-03Clinical Trial Update: Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors [EARLY_Phase 1]
An early-phase window-of-opportunity trial assessed whether the PARP inhibitor rucaparib modulates PD-L1 expression in triple-negative breas…
-
CLINICAL_TRIALS trial_result · 2024-10-02Clinical Trial Update: Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy [Phase 2]
Phase 2 trial update on atorvastatin in patients with stage IIb-III triple-negative breast cancer who did not achieve pathologic complete re…
-
CLINICAL_TRIALS trial_result · 2024-09-20Clinical Trial Update: Comparison of TP and TAC Regimens in Neoadjuvant Treatment of TNBC [Phase 2]
A Phase 2 neoadjuvant trial comparing TP and TAC regimens in triple-negative breast cancer has completed.
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer [Phase 2]
Phase 2 neoadjuvant trial evaluating enzalutamide plus paclitaxel in stage I-III androgen receptor-positive triple-negative breast cancer ha…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations [Phase 2]
Phase 2 trial of PARP inhibition in triple-negative breast cancer with BRCA1/2 mutations completed; results have been posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-09-04Clinical Trial Update: Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating an omega-3 fatty acid-based anti-cancer therapy in patients with metastatic triple-negative inflammato…
-
CLINICAL_TRIALS trial_result · 2024-08-26Clinical Trial Update: Sitravatinib in Metastatic Breast Cancer [Phase 2]
Phase 2 trial of sitravatinib in metastatic breast cancer, including triple-negative breast cancer, was terminated with results posted in 20…
-
CLINICAL_TRIALS trial_result · 2024-08-23Clinical Trial Update: Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC [Phase 1]
Pfizer's Phase 1 trial of a vaccine-based immunotherapy regimen for non-small cell lung cancer and triple-negative breast cancer was termina…
-
CLINICAL_TRIALS trial_result · 2024-08-22Clinical Trial Update: A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors [Phase 1, Phase 2]
Cantargia AB's CAN04 first-in-human study in solid malignant tumors (Phase 1/2) has completed. The trial encompassed several indications, in…
-
CLINICAL_TRIALS trial_result · 2024-08-21Clinical Trial Update: Molecular Subtyping of Triple-negative Breast Cancer and African Ancestry-related Immunogenicity
A completed clinical trial investigating molecular subtypes of triple-negative breast cancer and potential immunogenic differences related t…
-
CLINICAL_TRIALS trial_result · 2024-08-21Clinical Trial Update: A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer [Phase 3]
Phase 3 trial comparing atezolizumab plus adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in operable triple-nega…
-
CLINICAL_TRIALS trial_result · 2024-08-20Clinical Trial Update: Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating pembrolizumab in combination with binimetinib in locally advanced or metastatic triple-negative breast c…
-
CLINICAL_TRIALS trial_result · 2024-08-15Clinical Trial Update: A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) [Phase 2]
Phase 2 study MK-2140-002 evaluating Zilovertamab vedotin (VLS-101) in solid tumors including triple-negative breast cancer and non-small-ce…
-
CLINICAL_TRIALS trial_result · 2024-08-09Clinical Trial Update: CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating the combination of CFI-400945 and Durvalumab in advanced triple-negative breast cancer; results were poste…
-
CLINICAL_TRIALS trial_result · 2024-08-09Clinical Trial Update: QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. [Phase 1, Phase 2]
A Phase 1/2 trial of ImmunityBio's NANT TNBC vaccine (QUILT-3.067) for triple-negative breast cancer that progressed after standard therapy …
-
CLINICAL_TRIALS trial_result · 2024-08-01Clinical Trial Update: Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC) [Phase 3]
Phase 3 trial evaluating trilaciclib in combination with gemcitabine and carboplatin for metastatic triple-negative breast cancer has comple…
-
CLINICAL_TRIALS trial_result · 2024-07-31Clinical Trial Update: Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss [Phase 3]
A Phase 3 study evaluating alpelisib with nab-paclitaxel in advanced triple-negative breast cancer with PIK3CA mutation or PTEN loss was ter…
-
CLINICAL_TRIALS trial_result · 2024-07-30Clinical Trial Update: A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors [Phase 2]
A Phase 2 trial evaluating Cediranib in combination with Olaparib in advanced solid tumors has posted results as of 2024-07-30. Indications …
-
CLINICAL_TRIALS trial_result · 2024-07-26Clinical Trial Update: Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer [Phase 2]
A Phase 2 trial evaluating ipatasertib in combination with non-taxane chemotherapy for advanced or metastatic triple-negative breast cancer …
-
CLINICAL_TRIALS trial_result · 2024-07-09Clinical Trial Update: Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer [Phase 2]
Phase 2 trial evaluating Imprime PGG in combination with pembrolizumab in advanced melanoma and triple-negative breast cancer has completed,…
-
CLINICAL_TRIALS trial_result · 2024-07-05Clinical Trial Update: A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) [Phase 1]
This update reports the completion of a Phase 1 study (DUET-3) evaluating XmAb23104 in patients with selected advanced solid tumors.
-
CLINICAL_TRIALS trial_result · 2024-07-05Clinical Trial Update: Vaccination of Triple Negative Breast Cancer Patients [Phase 1, Phase 2]
Clinical trial update reporting completed Phase 1/Phase 2 results for a vaccination approach in patients with triple-negative breast cancer.
-
CLINICAL_TRIALS trial_result · 2024-06-18Clinical Trial Update: Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer [Phase 2]
A phase II trial evaluating carboplatin and paclitaxel with or without atezolizumab before surgery in newly diagnosed stage II–III triple-ne…
-
CLINICAL_TRIALS trial_result · 2024-06-12Clinical Trial Update: A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies [Phase 1, Phase 2]
A phase 1/2 study of sacituzumab in combination with chemoimmunotherapy for advanced triple-negative breast cancer has been terminated, with…
-
CLINICAL_TRIALS trial_result · 2024-06-04Clinical Trial Update: First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC [Phase 2]
This Phase 2 trial of first-line atezolizumab, paclitaxel, and bevacizumab in metastatic triple-negative breast cancer has completed.